Financial Solutions Advisory Group Inc. Sells 3,939 Shares of Moderna, Inc. $MRNA

Financial Solutions Advisory Group Inc. lowered its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 76.7% during the third quarter, Holdings Channel reports. The firm owned 1,198 shares of the company’s stock after selling 3,939 shares during the period. Financial Solutions Advisory Group Inc.’s holdings in Moderna were worth $231,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Physician Wealth Advisors Inc. boosted its holdings in Moderna by 8.3% in the third quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock worth $171,000 after purchasing an additional 68 shares in the last quarter. Fortitude Family Office LLC increased its position in Moderna by 53.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after buying an additional 77 shares during the last quarter. TD Waterhouse Canada Inc. increased its position in Moderna by 2.6% during the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock worth $246,000 after buying an additional 85 shares during the last quarter. SteelPeak Wealth LLC raised its holdings in Moderna by 3.9% during the third quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company’s stock valued at $654,000 after buying an additional 127 shares in the last quarter. Finally, Western Pacific Wealth Management LP bought a new position in Moderna during the third quarter valued at about $29,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. The trade was a 2.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 in the last 90 days. 10.80% of the stock is owned by company insiders.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer vaccine candidate recently produced positive clinical-trial data, renewing investor optimism about a potentially significant oncology business. The upcoming Nov. 6 event or update could provide another near-term catalyst. Will Moderna Soar on Nov. 6?
• Positive Sentiment: CEO Stéphane Bancel defended the melanoma-vaccine results, saying the data should improve over time and that Moderna’s technology may be difficult for competitors to replicate. He also expressed confidence that the platform could work in cancers beyond melanoma. Moderna CEO Cancer Vaccine Commentary
• Neutral Sentiment: Moderna’s ESMO presentation highlighted the science behind its oncology pipeline, but investors now want evidence that the program can translate into commercial revenue and improve the company’s financial outlook. Moderna ESMO Presentation
• Neutral Sentiment: Heavy investor searches for Moderna indicate elevated market interest, but the coverage does not identify a new fundamental development by itself. Investors Heavily Search Moderna
• Negative Sentiment: William Blair lowered Moderna to Market Perform from Outperform, citing valuation concerns after the stock’s strong oncology-driven advance. The downgrade suggests much of the cancer-vaccine optimism may already be reflected in the shares. William Blair Downgrades Moderna
• Negative Sentiment: An analyst lowered the FY2028 EPS estimate, reinforcing concerns about Moderna’s path to profitability and the premium valuation investors are assigning to its future pipeline. Comparisons with GSK emphasize that Moderna offers greater oncology upside but less income and currently higher execution risk. GSK vs. Moderna Growth Comparison

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent analyst reports. Barclays upped their price target on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 24th. Citigroup reaffirmed a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. Brookline Capital Markets reiterated a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $130.00 price target on shares of Moderna in a report on Wednesday, August 19th. Finally, Berenberg Bank lifted their price target on shares of Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research report on Friday, September 11th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $107.10.

Moderna Stock Up 4.0%

MRNA stock opened at $222.76 on Friday. The stock has a market capitalization of $88.93 billion, a price-to-earnings ratio of -27.88 and a beta of 1.09. The company has a 50-day moving average of $180.72 and a two-hundred day moving average of $85.58. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $254.48. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the company posted ($2.13) earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, equities research analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.